Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
  • C12N9/14—Hydrolases (3)
  • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
  • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2319/00—Fusion polypeptide
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
  • G01N2333/90—Enzymes; Proenzymes
  • G01N2333/914—Hydrolases (3)
  • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates

Definitions

• Glycans have several distinct properties that make their development as disease biomarkers appealing. Their location on cell surfaces makes them the first point of contact for cellular interactions and thus they are crucial in the control of normal metabolic processes. They also function as pathogen adhesion receptors. Glycan structures that are absent or are present in low amounts in a normal state on glycoprotein can proliferate or alter their sequence in disease states. A distinguishing feature of many glycans is a terminal sialic acid.
• the present invention provides novel sialic acid-recognizing affinity reagents.
• the affinity reagents recognize, and bind to, sialic acid (also referred to as 5-(acetylamino)-3,5-dideoxy-D- glycero- -O-galacto-non-2-u ⁇ opyranosomc acid, Neu5Ac, N-acetyl neuraminic acid, NANA, and Sia) that is present on a glycosylated biomolecule, such as a glycoprotein, glycopeptide, glycolipid, oligosaccharide, or polysaccharide.
• sialic acid also referred to as 5-(acetylamino)-3,5-dideoxy-D- glycero- -O-galacto-non-2-u ⁇ opyranosomc acid, Neu5Ac, N-acetyl neuraminic acid, NANA, and Sia
• a glycosylated biomolecule such as a glycoprotein
• the sialic acid-recognizing affinity reagents provided herein are engineered Lectenz ® -type proteins that have affinity and specificity for sialylated glycans.
• Lectenz ® is a registered trademark of Glycosensors and Diagnostics (d/b/a Lectenz ® Bio).
• Embodiments of the engineered sialic acid- recognizing affinity reagent of the invention include, without limitation: 1) pan-specific sialic acid- recognizing affinity reagents with broad specificity for sialo-glycans independent of linkage ( ⁇ 2,3-, ⁇ 2,6-, and ⁇ 2,8- linkages) (referred to herein as a Sia-PS reagent), with a lead candidate Sia-PSl, described in Example I; and 2) a2,3 sialic acid-recognizing affinity reagents specific for a2,3- linked sialo-glycans over a2,6, and a2,8 linkages (referred to herein as a Sia-3S reagent) with a lead candidate, Sia-3S1, described in Example II. These reagents have low or no affinity for non- sialylated glycans or peptide backbones.
• the sialic acid-recognizing affinity reagents of the invention have enhanced substrate specificity compared to antibodies or lectins that bind to sialic acid.
• the substrate specificity is tunable, as evidenced by comparing the Sia-PS affinity reagents and the Sia-3S affinity reagents described herein.
• Substrate specificity need not be context dependent, and the affinity reagents may be evolved to have desirable binding kinetics.
• the affinity reagents of the invention can be as efficiently produced as monomeric proteins.
• structurally guided genetic manipulations of S. pneumoniae NanB carbohydrate processing enzyme were used to identify sites for mutation, and select mutants with enhanced affinity for sialic acid, thereby converting NanB into a high specificity affinity reagent, known as a Lectenz ® .
• Design and synthesis methods are described, in general, in US Pat. Pub. US2012/0040474 ("Glycan-Specific Analytical Tools") and WO2015/161201 (U.S. Ser. No.
• the sialic acid-recognizing affinity reagent of the invention is useful in both research and clinical settings. For example, it is useful for the detection of disease related sialic acid
• the affinity reagent may be employed as a capture reagent or recognition element in a variety of applications for the discovery of glycan-based disease markers, as well as in the quality control analysis of recombinantly produced biopharmaceuticals, many of which are glycoproteins such as antibodies.
• These reagents can be adapted for such platforms as affinity chromatography enrichment, Western blot, or FACS-based detection.
• FIG. 1 shows a three-dimensional representation of S. pneumoniae NanB.
• FIG. IB is rotated 90 degrees from the view of FIG. 1 A.
• NanB is shown in complex with a substrate, 2,7-anhydro-Neu5Ac, shown as a sphere, bound to the NanB active site.
• FIG. 2 shows a flowchart outlining the key steps in Lectenz ® engineering.
• FIG. 3 A shows a model of 3'sialyllactosamine (3'SLN, stick) bound to enzyme with residues proximal ( ⁇ 4.5 A) to sialic acid shown in left panel as shaded residues and those proximal to the Gal/GlcNAc residues of 3 ' SLN shown in right panel as shaded residues.
• FIG. 3B shows a sequence display of wild-type Streptococcus pneumoniae NanB (PDB ID: 2vw0).
• the 697 amino acid sequence (SEQ ID NO: 1) is depicted and annotated.
• the three domains are labeled 2vwOA01, 2vwOA02, 2vwOA03.
• the image is from the RCSB PDB
• FIG. 3C shows an alignment of amino acid sequences of NanA (PDB ID 2VVZ; SEQ ID NO:
• NanB and NanC have 50% sequence identity and both share 25% identity with NanA.
• "*” refers to fully conserved; “:” refers to conservation between groups of amino acids with strongly similar properties; and “.” refers to conservation between groups of amino acids with weakly similar properties.
• FIG. 3D shows an alignment of wild-type NanB (PDB ID 2VW0; SEQ ID NO: 1) with the NanB fragment (30-697; SEQ ID NO:4) that is expressed from a pET28a+ based plasmid
• NanB:AA30-697(pET28a) in Example I. Residues 1-29 in wild-type NanB represent a signal or leader sequence. "*” refers to fully conserved; “:” refers to conservation between groups of amino acids with strongly similar properties; and “.” refers to conservation between groups of amino acids with weakly similar properties.
• FIG. 4 shows relative enzymatic activity of NanB and Lectenz ® clones.
• FIG. 5 shows BLI sensograms for the binding of Lectenz ® candidates to 3' SL immobilized on biosensors.
• FIG. 6 shows BLI sensograms for the binding of Sia-PS Lectenz ® candidates (analytes) to immobilized oligosaccharides.
• Lsp lactose (no sialic acid)
• 3' SL a2,3-sialyllactose
• 6' SL a2,6-sialyllactose
• GD3 GD3 oligosaccharide that contains a terminal a2,8-linked Neu5Ac residue and an internal a2,3-linked Neu5Ac residue.
• KD (6' SL) 0.69 ⁇
• KD (GD3) 0.30 ⁇ .
• FIGs. 7A, 6B, and 6C show separation of sialylated and non-sialylated proteins by Sia-PSl Lectenz ® affinity chromatography (LAC).
• a purified Sia-PSl sample (2 mg) was coupled chemically to a 1-mL sepharose column, followed by loading of an analyte. After competitive elution, the column was regenerated for the binding and elution of the next analyte. Experiments were performed on an AKTA Pure chromatography system.
• FIG. 7A shows the flow-through of non-sialylated glycoprotein horseradish peroxidase (HRP) and retention of fetuin in overlaid chromatograms.
• HRP horseradish peroxidase
• FIG. 7B shows an elution profile showing the separation of a mixture of BSA (non-glycosylated) and fetuin (sialylated glycoprotein).
• FIG. 7C shows an elution profile showing the separation of a mixture of asialofetuin (de-sialylated fetuin) and fetuin.
• FIGs. 8 A and 7B show LAC elution profiles for Sia-PSl and synthetic neoglycoproteins.
• FIG. 8A shows a Sia-PSl LAC elution profile of 3'-sialyllactose-BSA.
• FIG. 8A shows a Sia-PSl LAC elution profile of 6'-sialyllactose-BSA.
• Each analyte (200 ⁇ g) was applied onto the LAC column in binding buffer, washed and competitively eluted under gravity flow.
• the LAC column used was the same as the one described in FIG. 7. Protein concentration of collected fractions was determined by spectrophotometric absorption at 280 nm. For comparison purpose (see FIG.
• the neoglycoproteins were each loaded at 200 ⁇ g in 1 mL buffer volume to match the recommendation for a typical 1-mL lectin affinity columns. In each experiment, the amount of loaded analyte was nearly fully recovered by competitive elution.
• FIGs. 9A and 8B show elution profiles for standard lectin affinity columns and synthetic neoglycoproteins:
• FIG. 9 A shows an elution profile for 3'-sialyllactose-BSA (200 ⁇ g) from a commercially available MAA column.
• FIG. 9B shows an elution profile for 6'-sialyllactose-BSA (200 ⁇ g) from a commercially available SNA column.
• FIGs. 10A, 10B and IOC show Sia-PSl LAC enrichment of sialo-glycoconjugates from
• FIG. 10A shows a LAC profile showing the separation of the unbound proteins (flow-through peak; 319 ⁇ g) at the binding step and the bound proteins (elution peak; 30 ⁇ g).
• FIG. 10B shows SDS-PAGE of CFE (-125 ⁇ g loaded) and LAC elution fraction ( ⁇ 7 ⁇ g loaded).
• FIG. IOC shows MALDI profiles showing enrichment of small molecules in the LAC elution fraction. Note that the mass
• spectrometer used for the MALDI experiment is not sensitive enough to resolve molecules larger than 15 kD in size.
• FIG. 11 shows glycan array screening results for Sia-PSl indicating the ability to
• FIG. 12 shows amino acid iceLogo of enriched clone sequences.
• the wildtype sequence is shown across the bottom.
• Preferred amino acids at the five randomized positions are shown as a graphical representation.
• Y-axis indicates percentage of detection (% difference) for each amino acid.
• the prevalence of wild-type sequence at D237 and S673 is ignored by the iceLogo, hence a blank space at the top of the iceLogo for these positions.
• FIG. 13 shows enzymatic activity of wild-type (wt) NanB, the R193A point mutant, and Sia-3S Lectenz ® candidates.
• FIG. 14A shows a BLI sensogram for the binding of Sia-3S1 (analyte) to oligosaccharides using a buffer composed of 10 mM EPPS, 10 mM NaCl, pH 7.5.
• FIG. 13B shows a BLI sensogram for the binding of Sia-3S1 (analyte) to oligosaccharides using a buffer composed of 10 mM EPPS, 25 mM NaCl, pH 7.5.
• FIG. 15 shows differential elution of fetuin bound to a Sia-3S1 LAC column.
• Purified Sia- 3S1 (2 mg) was covalently coupled to a 1-mL sepharose column, followed by loading of 100 ⁇ g fetuin.
• Fetuin molecules bound onto the Sia-3S1 column were competitively eluted with a 50 mM 3' SL or 6'SL solution in loading buffer. (The A280 UV spike at 18 mL retention volume is an instrument pump artifact.)
• FIGs. 16A and 16B show Sia-3S1 LAC chromatography demonstrating selective binding to 3' SL-BSA over 6'SL-BSA.
• FIG. 16A shows results for 100 ⁇ g 3'SL-BSA loaded onto the Sia-3S1 LAC column.
• FIG. 16B shows results for 100 ⁇ g 6'SL-BSA loaded onto the Sia-3S1 LAC column.
• Sialylated BSA molecules bound onto the Sia-3S1 column were competitively eluted with 50 mM 3' SL or 6'SL solution before regeneration with 10 mM EPPS (pH 7.5) buffer containing 1 M NaCl ("NaCl regeneration"). Flow through amounts under each condition are approximately 5 ⁇ g.
• FIG. 17 shows that Sia-3S1 LAC column binds only to 3' SL-BSA using binding buffer with 110 mM NaCl. 50 ⁇ g 3'SL-BSA, or 6'SL-BSA was loaded onto the Sia-3S1 LAC column.
• Sialylated BSA molecules bound onto the Sia-3S1 column were eluted using 10 mM EPPS buffer (pH 7.5) with 1 M NaCl.
• FIG. 18 shows that Sia-PSl, Sia-PS4, Sia-PS5, and Sia-3S1 bind to their corresponding glycoconjugates.
• the sialic acid-recognizing affinity reagent of the invention can be referred to as a Lectenz ® , which term describes a novel class of engineered, lectin-like enzyme-derived reagents with specificity for glycan structures of biological significance.
• Lectenz ® reagents are engineered from a parent enzyme, but have little or no enzymatic activity, and have lectin-like carbohydrate-binding properties.
• Lectenz ® reagents retain the specificity of the endogenous parent enzymes from which they are engineered.
• the specificity of a Lectenz ® reagent is tuned to a similar glycan structure or motif. Lectenz ® reagents therefore have several advantages over either lectins or antibodies, including tunable specificity, tunable affinity, and ease of production.
• sialic acid-recognizing affinity reagents described herein offer numerous advantages over sialic acid-recognizing lectins, because they have been engineered to have high affinity, yet possess substrate specificity based on the carbohydrate processing enzyme, NanB.
• substrate specificity the sialic acid-recognizing affinity reagent may be the same as NanB.
• the substrate specificity the sialic acid-recognizing affinity reagent may be broader than NanB, i.e., it can be expanded or broadened, as in the pan-specific Sia-PS affinity reagents described herein.
• the substrate specificity of the sialic acid- recognizing affinity reagent may be narrower than NanB (enhanced or increased specificity).
• Sialidases remove sialic acid, a 9-carbon carbohydrate, as the terminal sugar of various glycoconjugates.
• the present invention utilizes S. pneumoniae NanB sialidase as the template for development of novel sialic acid-recognizing affinity reagents.
• a three- dimensional representation of S. pneumoniae NanB is shown in Figure 1.
• Panel B is rotated 90 degrees from the view of panel A.
• NanB is shown in complex with a substrate, 2,7-anhydro-Neu5Ac, shown as a sphere, bound to the NanB active site.
• the L-domain (lectin-like), also known as the CBM domain or CBM40 domain, constitutes the carbohydrate-binding module (CBM), which has been classified within the CBM40 family.
• CBM carbohydrate-binding module
• the catalytic N-domain also known as the glycosyl hydrolase (GH) domain, of the GH33 domain, which possesses neuraminidase activity, is also shown.
• a short linker (residues 225-230) connects the L-domain and the N-domain.
• An irregular domain, the I-domain is also shown.
• the approximate locations of the domains of NanB can be characterized as follows: a signal/leader sequence (residues 1-29), a CBM40 domain (residues 30-228), a catalytic domain (residues 229-345 and 459-697), and an irregular domain (residues 346-458).
• Active site include the classical sialidase arginine triad, Arg245, Arg557, and Arg619, as well as Tyr653,
• the NanB template can be SEQ ID NO: 1, or a truncated version of SEQ ID NO: 1.
• NanB template is exemplified by amino acids 30-697 of SEQ ID NO: 1.
• sialic acid is often used to refer to a family of acidic sugars with a nine-carbon backbone.
• the most common sialic acid found in mammalian cells is N-acetylneuraminic acid (Neu5 Ac, or NANA), which is acetylated at the C-5 position (Formula I).
• the numbering of the sialic acid structure begins at the carboxylate carbon and continues around the chain.
• the configuration that places the carboxylate in the axial position is the alpha- anomer (Formula II).
• sialic acid generally refers to Neu5Ac as described in Examples I and II but can, in the appropriate context, include other derivatives of neuraminic acid as well, such as variants that are hydroxylated at the C-5 position (e.g., ketodeoxynonic acid, Kdn), or that have a hydroxylated 5-N-acetyl group (e.g., N-glycolylneuraminic acid, Neu5Gc) or that are not N- acylated (e.g., neuraminic acid, Neu).
• ketodeoxynonic acid, Kdn ketodeoxynonic acid
• Kdn ketodeoxynonic acid
• Neu5Gc N-glycolylneuraminic acid
• neuraminic acid Neu
• Sialic acids can be present within a glycan at either a terminal position or an internal position. They can be found as a terminal saccharide component of biologically relevant N- glycans, O-glycans, and glycosphingolipids (gangliosides). They also are known to cap side chains of glycosylphosphatidylinositol (GPI) anchors. They may also be found as oligosialic acids or polysialic acids. Varki et al., "Sialic Acids," Ch. 14 in Essentials of Glycobiology, 2 nd Ed.
• Sialic acids may be present as a component of oligosaccharide chains of mucins, glycoproteins, glycopeptides, and glycolipids, including glycosphingolipids and glycolipopeptides. Typically, sialic acid is linked to another monosaccharide in an a-linkage.
• the sialic acid-recognizing affinity reagent of the invention recognizes (i.e., binds to) a sialic acid component an oligosaccharide.
• a sialic acid can be covalently bound to an adjacent monomer of the oligosaccharide in any of several linkage topographies. While two linkage conformations (a and ⁇ ) are possible, typically the linkage to the adjacent saccharide is in the a conformation. Linkage can occur at any of a number of positions on the adjacent monomer, such as the 3 position, 6 position, or 8 position of the adjacent monomer, resulting in an a2,3 linkage, an a2,6 linkage or an a2,8 linkage, respectively.
• the oligosaccharide containing the sialic acid can be a disaccharide (2 monomers) or a higher oligosaccharide (more than 2 monomers).
• the oligosaccharide can be a part of (i.e., a component of) a glycan structure that is present in a glycosylated biomolecule, such as a glycoprotein, glycopeptide, or glycolipid.
• the sialic-acid recognizing affinity reagents of the invention are based on, i.e., engineered from, the amino acid sequence of NanB, as exemplified by NanB from S. pneumoniae and shown in SEQ ID NO: l (the full wild-type amino acid sequence, including the leader peptide; Fig. 3C) and SEQ ID NO:4 (the amino acid sequence without the leader peptide; Fig. 3D).
• Exemplary mutation sites are listed in Table 1, and can include one or more sites designated as important for binding (e.g., R619, W674, R245, R676, Y653, S675, R264, H269, 1246, 1326, R557, and D327) and/or one or more sites designated as "tepid” or as making weak contributions to binding (e.g., E541, E669, S673, T539, L679, T268, P492, D270, Y671, A538, N353, N316, P660 and N683).
• sites designated as important for binding e.g., R619, W674, R245, R676, Y653, S675, R264, H269, 1246, 1326, R557, and D327
• sites designated as "tepid” or as making weak contributions to binding e.g., E541, E669, S673, T539, L679, T268, P492, D270, Y671, A538,
• affinity reagents engineered from NanB such as Sia-PSl, Sia- PS2, Sia-PS3, Sia-PS4, Sia-PS5, Sia-3S1, Sia-3S2, Sia-3S3, Sia-3S5, Sia-3S6, Sia-3S7, Sia-3S7*, Sia-3S8, Sia-3S9, which are engineered SEQ ID NO:4 and described in Examples I and II can, in some embodiments, include further modifications.
• they can include truncations at or additions to the ends of SEQ ID NO:4, for example truncations or additions of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids, and/or conservative mutations in regions not involved in activity or substrate binding, as long as the overall domain structure of the affinity reagent remains intact, and pan- specific binding to sialic acid (in the case of Sia-PS reagents) or specific binding to Siaa2,3 linkages (in the case of Sia-3S reagents) is preserved.
• sialic acid in the case of Sia-PS reagents
• Siaa2,3 linkages in the case of Sia-3S reagents
• some embodiments of the sialic acid-recognizing affinity reagent may contain the carbohydrate binding module (CBM) domain of NanB (e.g., residues from 30 through about 229 of SEQ ID NO: 1), but not the glycosyl hydrolase (GH) domain; other embodiments of the sialic acid-recognizing affinity reagent may contain the glycosyl hydrolase (GH) domain (e.g., residues from about 229 through 697 of SEQ ID NO: l), but not the carbohydrate binding module (CBM) domain of NanB.
• CBM carbohydrate binding module
• the sialic acid-recognizing affinity reagent is pan-specific in its recognition of (i.e., binding to) a sialic acid.
• This pan-specific affinity reagent recognizes a sialic acid (Neu5Ac) independent of the linkage configuration between the Neu5Ac and the adjacent saccharide.
• the linkage configurations recognized by the pan-specific affinity reagent include Siaa2,3-, a2,6-, and a2,8- linkages.
• the pan-specific sialic acid-recognizing affinity reagent also recognizes common modifications of Neu5 Ac, such as 9-0 acetylation, and variants of the N-glycolyl form of sialic acid.
• the pan-specific sialic acid-recognizing affinity reagent of the invention is exemplified by a NanB fragment (residues 30-697; SEQ ID NO:4) with a single mutation.
• Exemplary mutation sites include Y653, D270, and E541.
• Exemplary pan-specific affinity reagents, each having a single mutation in the NanB GH domain as noted, are shown in Table 2 and include Sia-PSl (Y653F), Sia-PS2 (D270A), Sia-PS3 (D270N), Sia-PS4 (E541A), and Sia-PS5 (E541Q).
• these single site mutations have a dual effect.
• Sia-PS2 and Sia-PS3 reduce (Sia-PS2 and Sia-PS3) or effectively eliminate (Sia-PSl, Sia-PS4, and Sia-PS5) catalytic activity, and they broaden specificity for sialic acid ligand binding.
• the pan-specific sialic acid-recognizing affinity reagent we chose for further validation study was Sia-PSl that contains the Y653F at active site residue Tyr653. This one mutation, which involves removal of a single hydroxyl group, not only eliminates enzyme activity, but astonishingly introduces pan-specific binding into the mutated, inactivated enzyme, despite its distance from the carbohydrate binding module (CBM) domain of the NanB.
• CBM carbohydrate binding module
• the sialic acid-recognizing affinity reagent is specific for a single sialic acid linkage configuration, namely, an a2,3 -linked sialic acid.
• These affinity reagents recognize (i.e., bind to) a sialic acid linked to the adjacent saccharide in an a2,3-linkage, but not a sialic acid linked to the adjacent saccharide in an a2,6-linkage or an a2,8-linkage.
• the linkage-specific sialic acid-recognizing affinity reagent of the invention is exemplified by a NanB fragment (residues 30-697; SEQ ID NO:4) with multiple mutations.
• mutations reduce or eliminate catalytic activity, and alter the binding specificity of the inactivated enzyme to make it specific for a2,3-linked sialic acid (versus a2,6-linked sialic acid and a2,8- linked sialic acid).
• Exemplary mutation sites include R193, D270, A538, E541, P660, S673, D327, and N683.
• Exemplary sialic acid-recognizing affinity reagents with heightened specificity for an a2,3-linked sialic acid are shown in Table 4, include the following, with mutations sites identified:
• Sia-3S7* is based on Sia-3S7, but without mutations D427Y and L690F. These two missing mutations are not expected to affect binding specificity.
• the invention also includes conjugates of the sialic acid-recognizing affinity reagent.
• a conjugate includes, as a first component, a sialic acid-recognizing affinity reagent, which is covalently linked to at least one second component, which may be a proteinaceous component or a nonproteinaceous component.
• a conjugate that includes a proteinaceous component can be synthesized as a fusion protein using well-known recombinant DNA methods.
• the conjugate includes a proteinaceous or non-proteinaceous component that is chemically or enzymatically conjugated to the sialic acid-recognizing affinity reagent.
• a conjugate of the invention includes a sialic acid-recognizing affinity reagent conjugated to a therapeutic agent, also referred to herein as a drug.
• This conjugate is analogous to the well-known antibody-drug conjugate (ADC) except that the sialic acid-recognizing affinity reagent is used in place of the antibody.
• Drugs that can be conjugated to a sialic acid- recognizing affinity reagent include, without limitation, cytotoxins, anti-metabolites, alkylating agents, antibiotics and anti-mitotic agents.
• Anti-cancer, anti-inflammatory, pro-inflammatory, and immune-moderating drugs are particularly suitable for conjugation to a sialic acid-recognizing affinity reagent, since cancerous and precancerous conditions, as well as inflammation and immune conditions, are often associated with changes in protein glycosylation patterns.
• a therapeutic or diagnostic radioactive agent can be coupled to or incorporated into a sialic acid-recognizing affinity reagent to yield a "Lectenz ® -drug" conjugate that can be targeted to a cancer glycomarker.
• the therapeutic or diagnostic agent can be targeted to mucus linings or membranes, such as in the lungs or gut.
• anti-viral and anti -bacterial drugs are also particularly suitable for incorporation into a "Lectenz ® -drug" conjugate, as targeting viral or bacterial glycosylated biomolecules has great therapeutic potential.
• a conjugate of the invention includes a sialic acid-recognizing affinity reagent conjugated to a diagnostic or detection agent.
• the diagnostic or detection agent can include a detectable label, including but not limited to a radioactive, fluorescent, phosphorescent, colorimetric, enzymatic, immunological, magnetic, paramagnetic, diamagnetic or electromagnetic label.
• a sialic acid-recognizing affinity reagent need not be conjugated to function as a diagnostic or detection agent, as the sialic acid-recognizing affinity reagent can be detected directly, e.g., via immunoassay.
• a conjugate of the invention includes a sialic acid-recognizing affinity reagent conjugated to a marker sequence, for example a peptide such as hexa-histidine or hemagglutinin, to facilitate purification.
• a marker sequence for example a peptide such as hexa-histidine or hemagglutinin
• fusion proteins that include a sialic acid-recognizing affinity reagent covalently linked to glutathione S-transferase (GST), thioredoxin, bovine serum albumin, bovine pancreatic trypsin inhibitor, or fluorescent proteins such as green fluorescent protein (GFP).
• GST glutathione S-transferase
• thioredoxin thioredoxin
• bovine serum albumin bovine pancreatic trypsin inhibitor
• fluorescent proteins such as green fluorescent protein (GFP).
• sialic acid-recognizing affinity reagents of the invention have many uses as diagnostic, therapeutic, bioengineering or research reagents in clinical or research settings. For example, changes in the normal levels of glycan structures such as terminal sialic acid may be markers of disease states. New highly specific reagents are thus desirable in order to overcome current limitations in the discovery and exploitation of disease-related glycans.
• the sialic acid-recognizing affinity reagent can be used to identify new, or detect previously identified, disease-associated sialic acid modifications of glycopeptides, glycoproteins and glycolipids.
• the sialic-acid recognizing affinity reagent is useful for the detection of sialic acid and analysis of markers relevant to prostate-specific antigen (PSA) and influenza virus.
• the sialic acid-recognizing affinity reagent can be employed as a research or diagnostic tool in an affinity matrix for sample enrichment and can, in conjunction with existing mass spectrometric based methods, provide linkage information, as further described below.
• sialic acid-recognizing affinity reagent can be utilized in any method can otherwise be performed with an anti-glycan antibody or a lectin.
• sialic acid-recognizing affinity reagents of the invention can be advantageously substituted for anti-glycan antibodies in numerous medical and laboratory methods, including diagnostic, analytical and therapeutic methods.
• the sialic acid-recognizing affinity reagents of the invention can be advantageously substituted for lectins in numerous diagnostic and analytical laboratory methods.
• a sialic acid- recognizing affinity reagent can be employed as a capture reagent, as in affinity chromatography enrichment, or in histological studies, Western blots, FACS-based detection, and the like.
• sialic acid-recognizing reagent of the invention can be a component of a multicomponent microarray that contains other Lectenz ® reagents and/or lectins, antibodies, or other carbohydrate-binding molecules, with varying specificities.
• the sialic acid-recognizing affinity reagents can be used for detection of sialic acid relevant for quality control in the manufacturing of biologies. More specifically, they can be used to detect the presence, absence, or linkage position of sialic acid on synthetic or recombinantly produced glycoprotein-based or glycolipid-based biologies, such as therapeutic antibodies, as step in quality control during synthesis or storage. Diagnostic and analytical methods
• a sialic acid-recognizing affinity reagent or conjugate thereof can be used to detect sialic acid-containing glycans in a biological or synthetic sample.
• a biological sample such as a tissue or fluid
• the sialic acid-recognizing affinity reagent or conjugate thereof alone or in conjunction with other analytical reagents, to detect and/or characterize the level or type of glycosylation and/or glycation in the biological sample.
• Characterization can include of the glycan can include identifying a constituent saccharide of the glycan, determining saccharide composition of the glycan, determining linkage positions within the glycan, or determining stereochemistry of the glycan.
• a sialic acid-recognizing affinity reagent or conjugate thereof can be used for quality control in the synthesis of therapeutic biologies, for example in the synthesis of therapeutic antibodies, to monitor the level or type of glycosylation. See PCT patent publication WO2012/118928, published September 7, 2012, and US Pat. Publ. 2014/0005069, published January 2, 2014.
• a sialic acid-recognizing affinity reagent or conjugate thereof can be utilized as an affinity reagent or as part of an affinity matrix; for example, it can be tethered to a solid support, such as a surface, column, resin, bead, particle or nanoparticle, and used in methods to detect or enrich for sialic acid-containing compounds in or from biological or synthetic samples. Tethered sialic acid-recognizing affinity reagents can also be used to isolate and/or purify synthetic glycosylated compounds.
• Diagnostics can be performed on a biological sample obtained from a subject, but can also be performed in vivo.
• a sialic acid-recognizing affinity reagent or conjugate thereof is administered to a subject, and binding of the sialic acid-recognizing affinity reagent within the subject is detected.
• a conjugate is administered to the subject, wherein the conjugate includes a detectable label so as to facilitate biomedical imaging.
• a suitable conjugate include a sialic acid-recognizing affinity reagent conjugated to a radiolabel, a
• paramagnetic label or a diamagnetic label.
• the sialic acid-recognizing affinity reagent can be used to interrogate biological samples in the search for abnormal glycosylation.
• biological samples include, but are not limited to, any biological fluid, tissue, or organ.
• the biological fluids include, but are not limited to blood, urine, serum, saliva, cerebra-spinal fluid, and semen.
• a sialic acid-recognizing affinity reagent can be used for a detection of the presence or amount of a target analyte in biological fluids and tissues.
• targets are exogenously consumed species, such as plant polysaccharides, carbohydrate-based drugs, and pathogens, whose surfaces are often coated in complex distinct glycans.
• the sialic acid-recognizing affinity reagent also has application in drug discovery and evaluation of biological activity of new gly can-based compounds.
• the sialic acid-recognizing affinity reagent can be used for diagnosing, and/or treating diseases manifested by abnormal glycosylation. It can be used to detect certain tumor antigens comprising glycoproteins, glycolipids, and/or a variety of carbohydrate epitopes. A number of these tumor antigens have been found to be up-regulated in the neoplastic disease state.
• CEA carcinoembryonic antigen
• CA 19-9 carbohydrate antigen 19-9
• Lewis A antigen which is present in a glycolipid found in patients with pancreatic cancer
• CA15-3 carbohydrate antigen 15-3
• the presence of the antigen does not necessarily indicate transformation to a cancerous cell; however, its localization in the cell is indicative, as in the case of CEA. For this reason, there is a need for highly selective and high affinity analytical tools.
• the diagnostic tests currently rely on antibodies that were often generated against the peptide portions of the glycoprotein or sugar portions of glycolipid, however, the exact epitopes are only now being defined. In the examples in which the glycans have been characterized, multiple glycoforms are often present (CEA, for example). Lacking reagents that are able to discriminate between glycoforms, it is currently impossible to determine the extent to which subtle variations in glycosylation correlate with disease state, cancer type, or tissue localization.
• the sialic acid-recognizing affinity reagent may have utility for quantifying the relative abundances of various glycoforms present for any given glycoprotein in a biological sample.
• glycoform refers to a protein with a specific glycan attached.
• glycoprotein can have multiple glycoforms. More specifically, a glycoform is an isoform of a protein that differs only with respect to the number or type of attached glycan; the amino acid sequence is the same for the various glycoforms. Glycoproteins often comprise a number of different glycoforms, with alterations in the attached saccharide or oligosaccharide.
• a sialic acid-recognizing affinity reagent can be used to enrich the biological sample for sialic acid-containing glycans. It can likewise be used to identify specific glycosylation sites on the protein surface to which the glycans are attached. It can also be used to separate intact glycopeptides from a proteolytic digest of a glycoprotein. Enriching the sample in the analyte of interest is of great assistance in the further characterization of the glycopeptides fractions. In particular, enrichment facilitates the identification of the peptide sequence and the glycan structure, which can enable the identification within the intact protein of the glycosylation sites and the characterization of the particular glycans present at each glycosylation site.
• the sialic acid-recognizing affinity reagent can be used in monitoring specific glycan modifications of proteins in biological fluids, tissues, organs, or living cells. Recognition is not expected to depend on the identity of the protein, and the sialic acid-recognizing affinity reagent is expected to be able to recognize any protein sequence that includes a sialic acid (consistent with the particular specificity of the sialic acid-recognizing affinity reagent, i.e., whether it is pan-specific or specific for a particular linkage), and therefore will be very useful for detection of particular glycan modifications.
• the sialic acid-recognizing affinity reagent can be used for in vitro or in vivo staining cells or tissues.
• the sialic acid-recognizing affinity reagent can be employed to monitor sialylation of glycans in a mixture, as might arise during the production of recombinant glycoproteins for use in the pharmaceutical or research industries.
• the sialic acid-recognizing affinity reagent can be tagged with a stain or a dye and applied to a biological sample comprising cells or tissues or glycoproteins or glycopeptides or oligosaccharides or polysaccharides of interest.
• sialic acid-recognizing affinity reagent of the present invention can be used as sialic acid-specific analytical tool.
• Glycan-specific analytical tools have potential use as a method of detection in many areas, including environmental, fermentation, food and medical areas and could be used for in vivo or in vitro sensing in humans or animals.
• the sialic acid-recognizing affinity reagent of the present invention can be used as an affinity reagent or as vehicle for tissue staining.
• the sialic acid-recognizing affinity reagent can be used for enriching a biological sample for sialic acid-containing glycans.
• the sialic acid-recognizing affinity reagent can be used to determine specific glycosylation sites on glycoproteins.
• the sialic acid-recognizing affinity reagent can be used as a reagent for affinity separation, including, for example, affinity chromatography.
• affinity chromatography is a method of separating biochemical mixtures, based on a highly specific biological interaction such as that between the binding protein and the glycan.
• the present invention is not limited to any specific design or chromatographic system.
• the sialic acid-recognizing affinity reagent will be either covalently attached or otherwise immobilized to the solid support, and will constitute a stationary phase.
• the stationary phase that is derivatized with the sialic acid-recognizing affinity reagent can be used in column chromatography.
• the particles of the solid stationary phase will be used to fill the whole inside volume of the tube (packed column).
• the solid phase particles will be concentrated on or along the inside tube wall leaving an open, unrestricted path for a biological sample (i.e., the mobile phase) in the middle part of the tube (open tubular column).
• the derivatized stationary phase can be used for batch chromatography.
• the stationary phase can be added to a vessel and mixed with the biological sample.
• the sialic acid-recognizing affinity reagent of the invention can be used as a therapeutic agent or modified for delivery of an active therapeutic agent. Since the sialic acid-recognizing affinity reagent of the present invention has a defined glycan specificity, a delivery of the therapeutic agents can be targeted only to those cells, tissues, or organs that display a biomolecule, such as a glycoprotein or glycolipid with the glycan structure recognized by the sialic-acid recognizing affinity reagent.
• sialic acid-recognizing affinity reagent to be used as a therapeutic in many applications such as targeted drug delivery. Changes in the levels and locations of sialic acid-containing glycans have been shown to be associated with many diseases, including cancer.
• the sialic acid-recognizing affinity reagent is thus expected to have direct applications in the field of cancer research, potentially leading to the development of a product for the detection of certain forms of cancer. It is also expected to have utility as a reagent for use in glycomics, wherein it may be used to enrich samples containing sialic acid-containing glycans, thereby enabling detection and analysis of these important carbohydrates.
• a sialic acid-recognizing affinity reagent can be used as a vehicle for targeted delivery of therapeutic agents.
• a sialic acid-recognizing affinity reagent, or conjugate thereof can be administered to a subject to treat or prevent an infection, disease, or disorder.
• the infection can be, for example, viral, bacterial, parasitic, or fungal.
• the disease or disorder can result from an exogenous agent, or it can be autologous or autoimmune.
• a sialic acid-recognizing affinity reagent is administered to a subject so as to bind to a sialic acid-containing glycan present within the subject, so as to achieve a therapeutic or prophylactic effect.
• the sialic acid-containing glycan can be an endogenous biomolecule produced by the subject, or it can be an exogenous biomolecule produced by a pathogen.
• the sialic acid-recognizing affinity reagent binds to an endogenous biomolecule, for example a biomolecule associated with cancer, a precancerous condition, or an immune disorder of the subject.
• the sialic acid-recognizing affinity reagent prevents binding of a pathogen to a host cell; in another embodiment, the sialic acid-recognizing affinity reagent prevents internalization of a pathogen into a host cell.
• a conjugate of a sialic acid-recognizing affinity reagent is administered to a subject, wherein the conjugate includes a therapeutic agent as exemplified above.
• the therapeutic agent can be an antibiotic agent, for example an agent that targets a microbial pathogen.
• the therapeutic agent can be an agent that targets an autologous or autoimmune disease, for example an anti-cancer agent, such as a cytotoxin, or an immunoactive agent.
• therapeutic agents that can be used for site-specific delivery include, but are not limited to, various chemotherapeutic, antibiotic, and antiviral agents, toxins, radioisotopes, cytokines, etc.
• a sialic acid-recognizing affinity reagent or conjugate thereof for therapeutic use can be tested for toxicity in suitable animal model systems, for example in rats, mice, monkeys, or rabbits.
• the usefulness of a sialic acid-recognizing affinity reagent or conjugate thereof to treat or prevent a viral infection can be assessed by evaluating its ability to inhibit viral replication, inhibit viral transmission or to treat or prevent symptoms associated with viral infection.
• the usefulness of a sialic acid-recognizing affinity reagent or conjugate thereof to treat or prevent a bacterial infection can be assessed by evaluating its ability to inhibit the bacterial replication, or to treat or prevent symptoms associated with bacterial infection.
• Usefulness in treating cancer can be evaluated by assessing the ability of a sialic acid-recognizing affinity reagent or conjugate thereof to inhibit the growth or metastasis of cancerous cells, to inhibit angiogenesis, or to cause cell death.
• the sialic acid-recognizing affinity reagent of the invention may be expressed in a host cell using genetic engineering techniques.
• the term "cell” is meant to include any type of biological cell.
• the host cell can be a eukaryotic cell or a prokaryotic cell.
• the host cell is a prokaryotic cell such as a bacterial cell; however single cell eukaryotes such as protists or yeasts are also useful as host cells.
• Preferred host cells are microbial cells, preferably the cells of single- celled microbes such as bacterial cells or yeast cells.
• the sialic acid-recognizing affinity reagent can be expressed without limitation in the cell of an animal, plant, insect, yeast, protozoan, bacterium, or archaebacterium.
• Paenibacillus Lactobacillus, Enterococcus, Arthrobacter, Brevibacterium, Corynebacterium Candida, Hansenula, Pichia and Saccharomyces.
• Preferred microbial cells include, without limitation, Escherichia coli, Bacillus subtilis, Bacillus licheniformis, Alcaligenes eutrophus, Rhodococcus erythropolis, Paenibacillus macerans, Pseudomonas putida, Enterococcus faecium, Saccharomyces cerevisiae, Lactobacillus plantarum, Enterococcus gallinarium and Enterococcus faecalis.
• a cell that has been genetically engineered to express the sialic acid-recognizing affinity reagent of the invention may be referred to as a "host” cell, a “recombinant” cell, a “genetically engineered” cell or simply an “engineered” cell. These and similar terms are used interchangeably.
• a genetically engineered cell contains one or more artificial sequences of nucleotides which have been created through standard molecular cloning techniques to bring together genetic material that is not natively found together. DNA sequences used in the construction of recombinant DNA molecules can originate from any species. For example, plant DNA may be joined to bacterial DNA, or human DNA may be joined with fungal DNA.
• DNA sequences that do not occur anywhere in nature may be created by chemical synthesis of DNA or by directed mutation of DNA, and incorporated into recombinant molecules. Proteins that result from the expression of recombinant DNA are often termed recombinant proteins. Examples of recombination are described in more detail below and may include inserting foreign polynucleotides (obtained from another species of cell) into a cell, inserting synthetic polynucleotides into a cell, or relocating or rearranging polynucleotides within a cell. Any form of recombination may be considered to be genetic engineering and therefore any recombinant cell may also be considered to be a genetically engineered cell.
• expression of a protein can be achieved through a number of molecular biology techniques.
• expression can be achieved by introducing into the host cell one or more copies of a polynucleotide encoding the desired protein.
• the polynucleotide encoding the desired protein may be endogenous or heterologous to the host cell.
• the polynucleotide is introduced into the cell using a vector; however, naked DNA may also be used.
• the polynucleotide may be circular or linear, single-stranded or double stranded, and can be DNA, RNA, or any modification or combination thereof.
• the vector can be any molecule that may be used as a vehicle to transfer genetic material into a cell.
• examples of vectors include plasmids, viral vectors, cosmids, and artificial chromosomes, without limitation.
• Examples of molecular biology techniques used to transfer nucleotide sequences into a microorganism include, without limitation, transfection, electroporation, transduction, and transformation. These methods are well known in the art. Insertion of a vector into a target cell is usually called transformation for bacterial cells and transfection for eukaryotic cells, however insertion of a viral vector is often called transduction.
• transformation, transfection, and transduction for the purpose of the instant invention, are used interchangeably herein.
• a polynucleotide which has been transferred into a cell via the use of a vector is often referred to as a transgene.
• the vector is an expression vector.
• An "expression vector” or “expression construct” is any vector that is used to introduce a specific polynucleotide into a target cell such that once the expression vector is inside the cell, the protein that is encoded by the polynucleotide is produced by the cellular transcription and translation machinery.
• an expression vector includes regulatory sequences operably linked to the polynucleotide encoding the desired protein. Regulatory sequences are common knowledge to the person of the skill in the art and may include for example, an origin of replication, a promoter sequence, and/or an enhancer sequence.
• the polynucleotide encoding the desired protein can exist extrachromosomally or can be integrated into the host cell chromosomal DNA. Extrachromosomal DNA may be contained in cytoplasmic organelles, such as mitochondria (in most eukaryotes), and in chloroplasts and plastids (in plants). More typically,
• the vector may further contain a selectable marker.
• selectable markers may be used to confirm that the vector is present within the target cell.
• Other selectable markers may be used to further confirm that the vector and/or transgene has integrated into the host cell chromosomal DNA.
• selectable markers is common in the art and the skilled person would understand and appreciate the many uses of selectable markers.
• the vector may further contain a reporter gene. Reporter genes may be used to confirm that the vector is expressing within the target cell, and may be further used to monitor the expression from the vector. The use of reporter genes is common in the art and the skilled person would understand and appreciate the many uses of reporter genes.
• a sialic acid-recognizing affinity reagent of the invention can be isolated and optionally purified from any genetically engineered cell described herein. It can be isolated directly from the cells, or from the culture medium, for example, during an aerobic or anaerobic fermentation process. Isolation and/or purification can be accomplished using known methods.
• kits that includes a sialic acid-recognizing affinity reagent, conjugate, fusion protein or affinity matrix of any of the preceding claims, and instructions for use.
• Embodiment 1 A sialic acid-recognizing affinity reagent comprising a catalytically inactive NanB neuraminidase protein, or fragment thereof, having at least one amino acid mutation compared to a corresponding wild-type NanB neuraminidase protein, wherein the mutation
• Embodiment 2 The sialic acid-recognizing affinity reagent of embodiment 1, wherein the NanB fragment comprises at least one of the carbohydrate binding module (CBM) domain of the NanB protein and the glycosyl hydrolase (GH) domain of the NanB protein.
• CBM carbohydrate binding module
• GH glycosyl hydrolase
• Embodiment 3 The sialic acid-recognizing affinity reagent of embodiment 1 or 2, wherein the affinity reagent is pan-specific for sialic acid.
• Embodiment 4 The sialic acid-recognizing affinity reagent of embodiment 3, wherein the affinity reagent binds to Neu5Ac linked to an adjacent saccharide monomer in an a2,3 linkage, Neu5Ac linked to an adjacent saccharide monomer in an a2,6 linkage, and Neu5Ac linked to an adjacent saccharide monomer in an a2,8 linkage.
• Embodiment 5 The sialic acid-recognizing affinity reagent of embodiment 3 or 4 which binds to at least one variant of Neu5Ac.
• Embodiment 6 The sialic acid-recognizing affinity reagent of any of embodiments 3-5, wherein the mutation is at a site selected from the group consisting of Y653, D270, and E541, as represented in SEQ ID NO: 1 or SEQ ID NO:4.
• Embodiment 7 The sialic acid-recognizing affinity reagent of embodiment 6, wherein the mutation is in S. pneumoniae NanB (SEQ ID NO: 1 or SEQ ID NO:4) or fragment thereof, or a corresponding position in a homologous NanB sequence.
• Embodiment 8 The sialic acid-recognizing affinity reagent of embodiment 6 or 7, wherein the mutation is selected from the group consisting of Y653F, D270A, D270N, E541A, and E541Q.
• Embodiment 9 The sialic acid-recognizing affinity reagent of embodiment 8, wherein the mutation is Y653F.
• Embodiment 10 The sialic acid-recognizing affinity reagent of embodiment 8 selected from the group consisting of Sia-PSl, Sia-PS2, Sia-PS3, Sia-PS4, and Sia-PS5.
• Embodiment 1 The sialic acid-recognizing affinity reagent of embodiment 10 which is Sia-PSl .
• Embodiment 12 The sialic acid-recognizing affinity reagent of embodiment 1 or 2, wherein the affinity reagent has a plurality of amino acid mutations compared to a corresponding wild-type NanB neuraminidase protein.
• Embodiment 13 The sialic acid-recognizing affinity reagent of embodiment 12, wherein said plurality of mutations comprises:
• Embodiment 14 The sialic acid-recognizing affinity reagent of embodiment 12 or 13, wherein the affinity reagent is specific for Neu5Ac that is linked to an adjacent saccharide monomer in an a2,3 linkage.
• Embodiment 15 The sialic acid-recognizing affinity reagent of any of embodiments 12-14, wherein the plurality of mutations are at sites selected from the group consisting of R193, D270, A538, E541, P660, S673, D327, and N683, as represented in SEQ ID NO: l or SEQ ID NO:4.
• Embodiment 16 The sialic acid-recognizing affinity reagent of embodiment 15, wherein the plurality of mutations are in S. pneumoniae NanB (SEQ ID NO: 1 or SEQ ID NO:4) or fragment thereof, or a corresponding position in a homologous NanB sequence.
• Embodiment 17 The sialic acid-recognizing affinity reagent of embodiment 15 or 16, wherein the plurality of mutations are selected from the group consisting of R193A, D270Q, D270G, D270H, D270I, A538V, A538W, A538F, A538H, A538M, A538I, E541D, E541A, E541I, E541 S, P660Q, S673A, S673Q, D327E, D327V, and N683S.
• Embodiment 18 The sialic acid-recognizing affinity reagent of embodiment 17, wherein the plurality of mutations comprise R193A, D270Q, A538V, and E541D.
• Embodiment 19 The sialic acid-recognizing affinity reagent of embodiment 17 selected from the group consisting of Sia-3S1, Sia-3S2, Sia-3S3, Sia-3S5, Sia-3S6, Sia-3S7, Sia-3S7*, Sia-3S8, and Sia-3S9.
• Embodiment 20 The sialic acid-recognizing affinity reagent of embodiment 19 which is Sia-PSl .
• Embodiment 21 The sialic acid-recognizing affinity reagent of any of the preceding embodiments, wherein the glycan is a constituent of a glycosylated biomolecule.
• Embodiment 22 The sialic acid-recognizing affinity reagent of embodiment 21, wherein the glycosylated biomolecule comprises a glycoprotein, a glycopeptide, a glycolipid, a
• glycolipoprotein or a glycolipopeptide.
• Embodiment 23 A conjugate comprising a first component comprising a sialic acid-recognizing affinity reagent of any of the preceding embodiments, covalently linked to a second component.
• Embodiment 24 The conjugate of embodiment 23, wherein the second component is a
• Embodiment 25 The conjugate of embodiment 23, wherein the second component is a
• Embodiment 26 The conjugate of any of embodiments 23-25 wherein the second component is a therapeutic or diagnostic agent.
• Embodiment 27 A fusion protein comprising a sialic acid-recognizing affinity reagent of any of embodiments 1 to 22.
• Embodiment 28 An affinity matrix comprising a sialic acid-recognizing affinity reagent, conjugate or fusion protein of any of the preceding embodiments.
• Embodiment 29. The affinity matrix of embodiment 28 selected from the group consisting of a solid support, surface, column, resin, bead, microarray, particle and nanoparticle.
• Embodiment 30 A kit comprising a sialic acid-recognizing affinity reagent, conjugate, fusion protein or affinity matrix of any of the preceding embodiments, and instructions for use.
• Embodiment 31 An isolated polynucleotide encoding a sialic acid-recognizing affinity reagent or conjugate of any of embodiments 1 to 24, or the fusion protein of embodiment 27.
• Embodiment 32 A vector comprising a polynucleotide of embodiment 31.
• Embodiment 33 The vector of embodiment 32, wherein the vector is an expression vector.
• Embodiment 34 A host cell comprising a vector of embodiment 32 or 33.
• Embodiment 35 The host cell of embodiment 34, wherein the host cell is a bacterial cell.
• Embodiment 36 A method for making the sialic acid-recognizing affinity reagent or conjugate of any of embodiments 1-24, or the fusion protein of embodiment 27, the method comprising expressing the affinity reagent, conjugate or fusion protein in host cell.
• Embodiment 37 A method for detecting a sialic acid component of a glycan, the method comprising:
• sialic acid-recognizing affinity reagent, conjugate or fusion protein of any of embodiments 1-27 under conditions to allow binding of the affinity reagent, conjugate or fusion protein to the sialic acid; and detecting the sialic acid.
• Embodiment 38 The method of embodiment 37, wherein the biological or laboratory sample comprises a recombinant antibody.
• Embodiment 39 The method of embodiment 37, wherein the glycan is a biomarker.
• Embodiment 40 The method of embodiment 39, wherein the biomarker is a cancer biomarker.
• Embodiment 41 A method for enriching, isolating or purifying a sialic acid-containing glycan, the method comprising:
• sialic acid-recognizing affinity reagent, conjugate or fusion protein of any of embodiments 1-27 under conditions to allow binding of the affinity reagent, conjugate or fusion protein to the sialic acid so as to yield an enriched, isolated or purified sialic acid-containing glycan.
• Embodiment 42 A diagnostic or therapeutic composition comprising a sialic acid-recognizing affinity reagent, conjugate or fusion protein of any of embodiments 1-27.
• Embodiment 43 The diagnostic or therapeutic composition of embodiment 42 wherein the sialic acid-recognizing affinity reagent, conjugate or fusion protein is detectably labeled.
• Embodiment 44 The diagnostic or therapeutic composition of embodiment 43 wherein the detectable label comprises a radioactive label, a fluorescent label, a phosphorescent label, a colorimetric label, an enzymatic label, an immunological label, a magnetic label, a paramagnetic label, a diamagnetic label or an electromagnetic label.
• the detectable label comprises a radioactive label, a fluorescent label, a phosphorescent label, a colorimetric label, an enzymatic label, an immunological label, a magnetic label, a paramagnetic label, a diamagnetic label or an electromagnetic label.
• Embodiment 45 Use of a sialic acid-recognizing affinity reagent, conjugate or fusion protein of any of embodiments 1-27 as a therapeutic agent.
• Embodiment 46 Use of a sialic acid-recognizing affinity reagent, conjugate or fusion protein of any of embodiments 1-27 as a diagnostic agent.
• Embodiment 47 Use of a sialic acid-recognizing affinity reagent, conjugate or fusion protein of any of embodiments 1-27 for targeted drug delivery.
• Embodiment 48 Use of a sialic acid-recognizing affinity reagent, conjugate or fusion protein of any of embodiments 1-27 for detection of the presence or amount of sialic acid in a biological or laboratory sample.
• Embodiment 49 A compound, composition, or method including one or more of the features described herein.
• this is the first reagent that is pan-specific for sialic acid (Sia, neuraminic acid, Neu5 Ac), and as such, it has the potential to significantly enhance sialo-glycan biomarker detection and glycomics enrichment.
• the flowchart presented in Figure 2 outlines schematically the methods employed in Example I and II to screen, optimize and select the Lectenz ® candidates.
• the specificity and affinity of potential Lectenz ® candidates is evaluated through structurally-guided site-specific and/or site- saturation mutagenesis assays designed to enable the selection of optimal clones.
• Bio-layer Interferometry (BLI) is used to determine the binding kinetics and affinities for binding to glycans and glycoproteins.
• Affinity chromatography is performed by immobilizing the Lectenz ® candidates in a column format to evaluate their ability to fractionate sialylated- and asialo-glycans and glycoconjugates. All promising Lectenz ® candidates are screened against the glycan array at the CFG, which currently contains over 600 O-and N-linked glycans. Results and Conclusions
• NanB is a well-characterized enzyme that recognizes sialylated glycan substrates. Its sequence and additional characteristics have been previously described in the literature [9].
• Table 2 Site mutations of selected pan-specific sialic acid-recognizing Lectenz ® reagents based on NanB. The shaded boxes indicate retention of the wild type amino acid at that site.
• Sia-PS Lectenz ® have no or attenuated enzymatic activity
• the neuraminidase activity of the wt NanB enzyme and its mutants was measured using, pNP- Neu5Ac as a colorimetric substrate.
• Sia-PS3 was 19% active
• Sia-PS2 was 9% active and others were inactive.
• Sia- PSl, Sia-PS4 and Sia-PS5 are suitable Lectenz ® candidates.
• Sia-PS Lectenz ® reagents have unique target affinity
• the affinity of Sia-PSl, Sia-PS4, and Sia-PS5 to 3'SL or 6'SL is comparable or superior to reported values for the lectins MAL ⁇ KD -1-3 ⁇ [16, 17]) and SNA (0.6 - 0.9 ⁇ [16]).
• Sia-PSl detects Neu5Ac independent of linkage
• Sia-PSl, Sia-PS2, Sia-PS3, Sia-PS4, and Sia-PS5 recognizes Neu5Aca2,3-, a2,6-, and a2,8- linkages present in 3' SL, 6' SL and the oligosaccharide of ganglioside GD3 (Neu5Aca2,8Neu5Aca2,3Gaipi,4GlcP), respectively.
• the binding affinity is micromlar or sub-micromolar for each of the oligosaccharides (Figure 6).
• Sia-PSl specifically binds to both 3'-sialylated and 6'-sialylated glycoproteins
• Sia-PSl is superior to lectins as an enrichment reagent for sialo-glycoconjugates
• Sia-PSl enriches sialo-glycoconjugates from MCF7 cell-free extract
• Sia-PSl LAC has been applied to enrichment of sialo-glycoconjugates from MCF7 cell-free extracts [18]. As shown in Figure 10, about 10% of the total proteins in the MCF7 extract were affinitive to the Sia-PSl LAC column and could be eluted by competitive reagent 3'SL & 6' SL. We were able to enhance binding efficiency by circulation of about 1.5 mg of MCF7 proteins through the column at 4°C overnight, which resulted in an eluted peak of 207 ⁇ g proteins, or 13.8%. It is expected that comparison of the identity and relative abundance of the Sia-PSl LAC-enriched proteins to known glycosylation databases will further demonstrate the specificity and effectiveness of Sia-PSl as a biomarker discovery reagent.
• the image ( Figure 18) shows that Sia-PSl, Sia-PS4, and Sia-PS5 bind sialylated proteins fetuin, 3' SL-BSA, and 6' SL-BSA, but not non-sialylated proteins asialofetuin and BSA.
• commercial biotinylated lectins MAL II and SNA known to be specific for SiaaSiaa2,3- and Siaa2,6 linkages, respectively, were used as probes.
• HRP streptavidin was used as the secondary detection reagent.
• the lectins did not bind their non-cognate BSA neoglycoprotein. This demonstrates that the Sia-PS Lectenz ® are pan-specific, unlike the commercial lectins.
• the Sia-PS Lectenz ® reagents have unique affinity, with Sia-PSl having the highest affinity.
• the Sia-PSl Lectenz ® is pan-specific for Siaa2,3-, a2,6-, and a2,8- linkages present in 3' SL,
• the Sia-PSl Lectenz ® is a functional capture reagent for the enrichment of fetuin from 50:50 mixtures of fetuimasialofetuin and fetuin:BSA.
• the Sia-PSl Lectenz ® is a functional capture reagent for the enrichment of both 3'- sialyllactose-BSA and 6'-sialyllactose-BSA glycoconjugates.
• the Sia-PSl Lectenz ® is a superior capture reagent for the enrichment of sialo- glycoconjugates compared to the lectins MAA and SNA.
• the Sia-PSl Lectenz ® is a functional capture reagent for the enrichment of sialo- glycoconjugates from a complex MCF7 breast cancer cell extract.
• the Sia-PSl Lectenz ® exhibits binding to sialylated glycans and no binding is observed to non-sialylated terminal galactose bearing glycans via glycan array screen.
• Example II Reagents Specific for a2,3 -Linked Sialic Acid
• Maackia amurensis leukoagglutinin (MAL) and hemagglutinin (MAH) are widely believed to be specific for the terminal glycan sequence Neu5Aca2,3Gaip. Yet remarkably, commercial Maackia lectins are often sold as mixtures, have multiple names (MAA, MAL I, MAL II, etc.), and have a range of reported specificities [5].
• these lectins have recently been screened against glycan arrays at the Consortium for Functional Glycomics, which confirmed that although they do bind to the Neu5Aca2,3Gaip sequence, they are equally able to bind to glycans terminating in other carbohydrates, including: 3S-Galp, 3S-GalNAcp, Neu5Gca2,3Galpb, Neu5Aca2,8Neu5Gca, and Neu5Gca2,8Neu5Gca (MAL), and 3S-Galp, KDNa2,3Galp, but not Neu5Gca (MAH).
• Library 2 and 3 were both biopanned against a 3' SL glycan target. Colonies from rounds 3, 6, and 9 were sequenced to identify enriched clones. Enriched yeast clones from library 3 were cloned into E. coli expression vectors for protein expression, purification, and characterization. Library 2 clones have also been sequenced and will be analyzed in a similar manner. An amino acid iceLogo representation of the candidates selected from library 3 is illustrated in Figure 12, indicating prevalence of different amino acids at each library mutagenesis residue. These candidates all contain an Arginine 193 residue to Alanine mutation (R193A) in addition to library mutations that are identified in Table 4.
• R193A Alanine mutation
• This R193A mutation is located in the carbohydrate binding module of NanB and has 88% enzymatic activity of wt NanB ( Figure 13).
• introduction of the R193A mutation to the Sia-3S Lectenz ® library prior to selection should attenuate pan-specific sialic acid binding, with little effect on candidate enzymatic activity. This will enhance enrichment of candidates that preferentially bind to 3' SL via directed evolution.
• Sia-3S Lectenz ® candidates are being characterized by BLI and their utility as capture reagents for enrichment of 2,3-linked sialic acid glycans is currently being assessed.
• a partial list of these Sia-3S Lectenz ® is included in Table 4, along with their mutations.
• the amino sequences of these mutants are represented by wild-type sequence SEQ ID NO:4 in Figure 3D modified at the amino acid sites as shown in Table 4. Physical and chemical properties of these candidate reagents are shown in Table 5.
• Table 4 Site mutations of selected 3 '-linkage specific sialic acid-recognizing Lectenz reagents from Library 3, based on NanB (R193A). The shaded boxes indicate retention of the wild type amino acid at that site.
• Sia-3S7 additionally has mutations D427Y and L690F; however, these were not among the sites selected for mutation (based on Table 1) and, rather, are artifacts of cloning.
• Sia-3S1 is specific for 3'SL over 6'SL Sia-3S1, which is enzymatically inactive, exhibits high 3'SL affinity under well-defined conditions.
• Figure 14 shows its BLI binding kinetics to 3' SL and 6'SL, respectively, in two different binding buffers.
• Sia-3S1 retains fetuin and is competitively eluted using 3'SL
• Preliminary Sia-3S1 LAC was performed on fetuin, a highly sialylated glycoprotein with both 3'-linked and 6'-linked sialic acid residues, followed by competitive elution with either 3' SL or 6'SL.
• 3'SL-BSA bound to a Sia-3S1 LAC column is competitively eluted by 3'SL but not 6'SL
• a Sia-3S1 LAC column was injected with 100 ⁇ g 3'SL-BSA (Figure 16A) or 6' SL-BSA ( Figure 16B) before eluting with 50 mM 3' SL or 6' SL.
• 3'SL is able to elute 90 ⁇ g of previously bound 3'SL-BSA. Attempting to elute bound 3' SL-BSA using 50 mM 6'SL only results in a small elution peak and the vast majority of 3' SL-BSA is eluted during the NaCl regeneration step.
• Sia-3S1 LAC column was injected with 50 ⁇ g 3' SL-BSA or 6' SL-BSA in 10 mM EPPS (pH 7.5) binding buffer containing 110 mM NaCl. Under these conditions, all 50 ⁇ g of 6' SL-BSA was detected in the flow through, whereas only 5 ⁇ g 3' SL- BSA did not bind to the column. Subsequently, bound 3' SL-BSA was eluted using 10 mM EPPS (pH 7.5) buffer with 1 M NaCl. No 6'SL-BSA elution could be detected using the same EPPS buffer with 1 M NaCl.
• the image ( Figure 18) shows that Sia-3S1 binds only proteins with a2,3-linked sialylation: fetuin and 3' SL- BSA. (A faint band for asialofetuin may be due to trace amounts of fetuin in the commercial asialofetuin.) It does not bind BSA and, significantly, does not bind 6'SL-BSA. This is in contrast to the "Siaa2,3 specific" MAL II lectin, which shows no binding, except for a very faint band for fetuin. A band would be predicted for 3 ' SL-BSA, but none was observed.
• Sia-3S1 Lectenz ® has preferential affinity for 3' SL over 6' SL.
• Sia-3S1 Lectenz ® is a functional capture reagent for the enrichment of 2,3-linked sialo- glycoproteins: more fetuin was eluted when using 3 'SL for competitive elution than 6'SL as a competitive elution reagent.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Molecular Biology (AREA)
• Biomedical Technology (AREA)
• Zoology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Genetics & Genomics (AREA)
• Organic Chemistry (AREA)
• Wood Science & Technology (AREA)
• Immunology (AREA)
• Biotechnology (AREA)
• General Health & Medical Sciences (AREA)
• Microbiology (AREA)
• Medicinal Chemistry (AREA)
• Biochemistry (AREA)
• Urology & Nephrology (AREA)
• Hematology (AREA)
• General Engineering & Computer Science (AREA)
• Analytical Chemistry (AREA)
• Food Science & Technology (AREA)
• Physics & Mathematics (AREA)
• Cell Biology (AREA)
• General Physics & Mathematics (AREA)
• Pathology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Peptides Or Proteins (AREA)
• Enzymes And Modification Thereof (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Medicinal Preparation (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Publications (2)

Family

ID=63919217

Family Applications (1)

Country Status (5)

Cited By (1)

Families Citing this family (3)

Citations (3)

Family Cites Families (24)

• 2018
  • 2018-04-24 AU AU2018258251A patent/AU2018258251B2/en active Active
  • 2018-04-24 EP EP18790482.6A patent/EP3615670A4/en active Pending
  • 2018-04-24 US US16/607,508 patent/US11434479B2/en active Active
  • 2018-04-24 WO PCT/US2018/029079 patent/WO2018200478A2/en not_active Ceased
  • 2018-04-24 JP JP2019557612A patent/JP7270141B2/ja active Active
• 2023
  • 2023-02-22 JP JP2023026222A patent/JP2023057175A/ja not_active Withdrawn

Patent Citations (4)

Non-Patent Citations (23)

Also Published As

Similar Documents

Legal Events